<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Newsroom

Press Releases

Our latest announcements

New Data Show Biodesix’s VeriStrat® Test is Cost-Saving, Improves Survival and Quality of Life in Advanced Lung-Cancer Patients

VeriStrat test saved an average of $1,050 per patient while improving survival outcomes (as compared to patients treated without the use of the test).

Biodesix Announces Data To Be Presented at AACR Annual Meeting 2017

Biodesix will present data from three studies at AACR 2017 annual meeting, on genomic and proteomic assays.

New Study Shows Biodesix’s VeriStrat Changes Treatment Decisions for Lung Cancer Patients; Reduces Over-Treatment at End of Life

A new study published in Current Medical Research and Opinion shows that VeriStrat changes treatment decisions for patients with lung cancer.

Study Results from Biodesix’s Immunotherapy Test Will Be Presented by Dr. Jeffrey Weber

Dr. Jeffrey Weber will present study results of new Biodesix immunotherapy test at ITOC4

Biodesix® and Progenetics Announce Distribution Agreement for Israel

Biodesix and Progenetics have entered into an international agreement; Biodesix tests will be available in Israel for the first time.

Blood-Based Diagnostic Assay Measures Immunotherapy Biomarker PD-L1

Biodesix released data at ASCO-SITC on a new assay that measures PD-L1 in the blood of cancer patients.

Biodesix to Present Study Data: Blood-Based Diagnostic Testing for PD-L1

Biodesix will present data on blood-based diagnostic testing for PD-L1 at ASCO-SITC 2017; ddPCR test measuring mRNA expression from immune and cancer cells

Genestrat Liquid Biopsy Testing™ Now Includes ROS1 and RET Mutations

Biodesix's GeneStrat liquid biopsy test now includes ROS1 and RET mutations. The test helps physicians make treatment decisions for cancer patients.

Clin-TOF Successfully Integrated into VeriStrat® Workflow

Clin-TOF successfully integrated into VeriStrat® workflow

Biodesix® and Bioyong Announce Agreement for Joint Development and Commercialization of VeriStrat® Test in Greater China

Biodesix and Bioyong announced a $38M deal for development and commercialization of VeriStrat in China.